Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Gerstner

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Expert Review of Anticancer Therapy|May 12, 2007
Primary CNS lymphomaElizabeth Gerstner, Tracy Batchelor
Neurology|July 13, 2005
Bi-hemispheric anterior cerebral artery with drop attacks and limb shaking TIAsElizabeth Gerstner, Bernardo Liberato, Clinton B Wright
Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology|March 16, 2007
A case of progressive apraxia of speech in pathologically verified Alzheimer diseaseElizabeth Gerstner, Ronald M Lazar, Christian Keller, et al.
The Journal of Clinical Investigation|September 4, 2013
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarateOvidiu C Andronesi, Otto Rapalino, Elizabeth Gerstner, et al.
Science Translational Medicine|January 13, 2012
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopyOvidiu C Andronesi, Grace S Kim, Elizabeth Gerstner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Blood|December 1, 2012
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaJames L Rubenstein, Jing Li, Lingjing Chen, et al.
Neuro-Oncology|February 13, 2020
Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastasesTimothy J Kaufmann, Marion Smits, Jerrold Boxerman, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Expert Review of Anticancer Therapy|May 12, 2007
Primary CNS lymphomaElizabeth Gerstner, Tracy Batchelor
Neurology|July 13, 2005
Bi-hemispheric anterior cerebral artery with drop attacks and limb shaking TIAsElizabeth Gerstner, Bernardo Liberato, Clinton B Wright
Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology|March 16, 2007
A case of progressive apraxia of speech in pathologically verified Alzheimer diseaseElizabeth Gerstner, Ronald M Lazar, Christian Keller, et al.
The Journal of Clinical Investigation|September 4, 2013
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarateOvidiu C Andronesi, Otto Rapalino, Elizabeth Gerstner, et al.
Science Translational Medicine|January 13, 2012
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopyOvidiu C Andronesi, Grace S Kim, Elizabeth Gerstner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Blood|December 1, 2012
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaJames L Rubenstein, Jing Li, Lingjing Chen, et al.
Neuro-Oncology|February 13, 2020
Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastasesTimothy J Kaufmann, Marion Smits, Jerrold Boxerman, et al.
Pageof 2